RxDoctor Payments DataLook up a doctor →

Mark Cascione, MD

Neurology · Tampa, FLNPI 1447249115

Payments from drug & device makers

$12,164,263in general payments, 2019–2025

Across 3,618 payments — averaging $3362.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$10M
  • Sanofi$988K
  • Genentech USA, Inc.$189K
  • Biogen$178K
  • E.r. Squibb & Sons, L.L.C.$166K
  • TG Therapeutics, Inc.$100K
  • plus $552K from 54 others
$11,114in research payments, 2019–2025

Across 6 payments — averaging $1852.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$11K
  • Sanofi US Services Inc.$468

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis302$9,991,201
Sanofi406$987,557
Genentech USA, Inc.263$189,146
Biogen318$177,601
E.r. Squibb & Sons, L.L.C.139$166,030
TG Therapeutics, Inc.124$99,792
Roche Products Limited119$84,901
Adamas Pharmaceuticals, Inc.74$79,150
EMD Serono, Inc.192$70,162
Bristol Myers Squibb171$59,799
Genentech, Inc.17$53,010
AstraZeneca(2 entities)120$41,586
Vanda Pharmaceuticals Inc.53$41,036
Johnson & Johnson(2 entities)63$31,795
Sanofi-aventis U.S. LLC24$27,000
F. Hoffmann-la Roche AG3$23,502
Sanofi US Services Inc.3$16,860
AbbVie(2 entities)207$4,828
Amgen(2 entities)97$1,992
Lundbeck LLC68$1,459
UCB, Inc.71$1,385
Teva Pharmaceuticals USA, Inc.127$1,314
Pfizer57$1,095
Lilly USA, LLC55$987
Octapharma USA, Inc.14$834
Neurocrine Biosciences, Inc.36$723
Takeda Pharmaceuticals U.S.A., Inc.25$710
Argenx US, Inc.28$660
Otsuka America Pharmaceutical, Inc.21$573
Biohaven Pharmaceuticals, Inc.32$524
Acorda Therapeutics, Inc21$509
CSL Behring22$439
Sunovion Pharmaceuticals Inc.30$400
Acadia Pharmaceuticals Inc21$395
Eisai Inc.17$380
Upsher-smith Laboratories LLC19$374
Amneal Pharmaceuticals LLC21$350
Avanir Pharmaceuticals, Inc.17$294
Mallinckrodt Hospital Products Inc.14$277
MDD US Operations, LLC15$241
GE HealthCare14$235
Banner Life Sciences, LLC14$225
Biohaven Pharmaceutical Holding Company Ltd.17$220
Merz Pharmaceuticals, LLC10$203
Arbor Pharmaceuticals, Inc.13$186
Harmony Biosciences LLC9$176
Supernus Pharmaceuticals, Inc.13$171
SK Life Science, Inc.5$166
Cycle Pharmaceuticals Inc8$163
Jazz Pharmaceuticals Inc.8$154
Sumitomo Pharma America, Inc.6$113
Axsome Therapeutics, Inc.4$109
Impel Pharmaceuticals LLC5$108
Akcea Therapeutics, Inc.5$89
Merz North America, Inc.4$77
Neurelis, Inc.5$77
Bayer5$73
Azurity Pharmaceuticals, Inc.4$73
Grifols USA, LLC3$69
Averitas Pharma Inc.3$57

How this compares

$12,164,263 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$2,790,379
Medicare patients
156
Services billed
51,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Tampa

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →